Literature DB >> 26681557

New-onset diabetes after liver transplantation: a national report from China Liver Transplant Registry.

Qi Ling1, Xiao Xu1, Haiyang Xie1, Kai Wang1, Penghui Xiang1, Runzhou Zhuang1, Tian Shen1, Jian Wu1, Weilin Wang1, Shusen Zheng1.   

Abstract

BACKGROUND/AIMS: New-onset diabetes after transplantation (NODAT) is a serious complication of liver transplantation (LT). The present study aimed to investigate the risk factors of NODAT by a national survey using the China Liver Transplant Registry database. PATIENTS: A total of 10 204 non-pre-existing diabetic patients undergone primary LT between January 2000 and December 2013 were included. Risk factors were identified by logistic regression analysis.
RESULTS: NODAT occurred in 24.3% of liver recipients with a median follow-up time of 2.6 years, and was associated with a significantly lower patient survival. NODAT increased not only diabetes related complications (e.g., infection, kidney failure) but also biliary stricture and cholangitis. NODAT patients who received hypoglycaemic treatment had a worse prognosis and a higher hepatocellular carcinoma recurrence compared with those without treatment. New-onset hyperglycaemia (<30 days) was the major predictor of NODAT. Other risk factors included cold ischaemia time >9 h, recipient age >50 years, body mass index >25 kg/m(2) , other hepatitis (mainly hepatitis C), post-transplant intensive care unit stay >15 days, cytomegalovirus infection and corticosteroid at discharge.
CONCLUSIONS: The incidence of NODAT in China is similar to that in Western countries. However, the NODAT-related complications are more common and severer in China compared with those in Western countries. The major risk factors are different.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  liver transplantation; new-onset diabetes after transplantation; prognosis; risk factors

Mesh:

Substances:

Year:  2016        PMID: 26681557     DOI: 10.1111/liv.13042

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  17 in total

1.  The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Authors:  Chenzhi Zhang; Kangchen Chen; Rongli Wei; Guanghan Fan; Xuechun Cai; Li Xu; Beini Cen; Jianguo Wang; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2020-03-27

2.  New-onset diabetes after adult liver transplantation in the Korean Organ Transplantation Registry (KOTRY) study.

Authors:  Jong Man Kim; Shin Hwang; Kwang-Woong Lee; Jae-Geun Lee; Je Ho Ryu; Bong-Wan Kim; Dong Lak Choi; Young Kyoung You; Dong-Sik Kim; Yang Won Nah; Koo Jeong Kang; Jai Young Cho; Geun Hong; In Seok Choi; Hee Chul Yu; Dongho Choi; Myoung Soo Kim
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

3.  The need for deepened molecular mechanism exploration in new onset diabetes after transplantation (NODAT).

Authors:  Ke Zhang; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

Review 4.  Post-transplant diabetes mellitus in patients with solid organ transplants.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Endocrinol       Date:  2019-03       Impact factor: 43.330

5.  Posttransplant Diabetes Mellitus Incidence and Risk Factors in Adult Liver Transplantation Recipients.

Authors:  N Gulsoy Kirnap; M Kirnap; O Alshalabi; N B Tutuncu; M Haberal
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Oct-Dec       Impact factor: 0.877

6.  Predicting short-term survival after liver transplantation on eight score systems: a national report from China Liver Transplant Registry.

Authors:  Qi Ling; Haojiang Dai; Runzhou Zhuang; Tian Shen; Weilin Wang; Xiao Xu; Shusen Zheng
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

7.  Evaluation of Angiotensinogen M235T and T174M Polymorphisms, Demographic and Clinical Factors in New-Onset Diabetes after Liver Transplantation in Iranian Patients.

Authors:  S Mottaghi; N Azarpira; A Dehshahri; B Khalvati; S Namazi
Journal:  Int J Organ Transplant Med       Date:  2019

8.  Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial.

Authors:  Elisabeth Schwaiger; Simon Krenn; Amelie Kurnikowski; Leon Bergfeld; María José Pérez-Sáez; Alexander Frey; David Topitz; Michael Bergmann; Sebastian Hödlmoser; Friederike Bachmann; Fabian Halleck; Susanne Kron; Hildegard Hafner-Giessauf; Kathrin Eller; Alexander R Rosenkranz; Marta Crespo; Anna Faura; Andrea Tura; Peter X K Song; Friedrich K Port; Julio Pascual; Klemens Budde; Robin Ristl; Johannes Werzowa; Manfred Hecking
Journal:  J Am Soc Nephrol       Date:  2021-08       Impact factor: 14.978

9.  Prevalence, predictive factors, and survival outcome of new-onset diabetes after liver transplantation: A population-based cohort study.

Authors:  Fu-Chao Liu; Jr-Rung Lin; Hsiu-Pin Chen; Yung-Fong Tsai; Huang-Ping Yu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Donor Graft MicroRNAs: A Newly Identified Player in the Development of New-onset Diabetes After Liver Transplantation.

Authors:  Q Ling; H Xie; J Li; J Liu; J Cao; F Yang; C Wang; Q Hu; X Xu; S Zheng
Journal:  Am J Transplant       Date:  2016-09-07       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.